Mechanistically, CAF‐derived EV‐packaged circTAX1BP1 is delivered to colorectal cancer (CRC) cells, where it binds to VIRMA and promotes its lactylation at lysine residue 1713 by recruiting AARS2. Here, VIRMA is linked to colorectal cancer.